Abstract
The results of the randomized trial by Fan et al. suggest that 'biocompatible' peritoneal dialysis solutions have no major advantage over standard solutions in peritoneal dialysis patients in relation to residual renal function (RRF) and technique survival. The possible effect of more biocompatible peritoneal dialysis solutions on RRF should be tested in patients starting peritoneal dialysis programs with relatively well-preserved RRF. When RRF is already very poor, it is very unlikely that a more biocompatible peritoneal dialysis solution can preserve highly damaged and sclerotic kidneys.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have